Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W; SOLO I, SOLO II Investigators.

Int J Antimicrob Agents. 2016 Nov;48(5):528-534. doi: 10.1016/j.ijantimicag.2016.07.019. Epub 2016 Sep 13.

PMID:
27665522
2.

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

Deck DH, Jordan JM, Holland TL, Fan W, Wikler MA, Sulham KA, Ralph Corey G.

Infect Dis Ther. 2016 Sep;5(3):363-5. doi: 10.1007/s40121-016-0127-9. No abstract available.

3.

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

Deck DH, Jordan JM, Holland TL, Fan W, Wikler MA, Sulham KA, Ralph Corey G.

Infect Dis Ther. 2016 Sep;5(3):353-61. doi: 10.1007/s40121-016-0119-9. Epub 2016 Jul 1. Erratum in: Infect Dis Ther. 2016 Sep;5(3):363-5.

4.

Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.

Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):110-2. doi: 10.1016/j.diagmicrobio.2008.05.010. Epub 2008 Jul 11.

PMID:
18620833
5.

Correction of a reference to clinical laboratory standards institute interpretive criteria.

Wikler MA, Ferraro MJ.

Clin Infect Dis. 2008 Jun 1;46(11):1798; author reply 1798-9. doi: 10.1086/588056. No abstract available.

PMID:
18462124
6.

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG.

Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7.

7.

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.

Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K, Saiman L.

Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1.

8.

In vitro antimicrobial activity of doripenem, a new carbapenem.

Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA.

Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96.

9.

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.

Gotfried M, Quinn TC, Gothelf S, Wikler MA, Webb CD, Nicholson SC.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):85-91.

PMID:
12376037
10.

Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.

Sher LD, Poole MD, Von Seggern K, Wikler MA, Nicholson SC, Pankey GA.

Otolaryngol Head Neck Surg. 2002 Sep;127(3):182-9.

PMID:
12297808
11.

Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.

Anzueto A, Gotfried M, Wikler MA, Russo R, Nicholson SC.

Clin Ther. 2002 Jun;24(6):906-17.

PMID:
12117081
12.

Perioperative antibiotic prophylaxis and wound infection following breast surgery.

Platt R, Zucker JR, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, Bryan CS, Burke JF, Wikler MA, Marino SK, et al.

J Antimicrob Chemother. 1993 Feb;31 Suppl B:43-8.

PMID:
8449845
13.

Prophylaxis against wound infection following herniorrhaphy or breast surgery.

Platt R, Zucker JR, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, Bryan CS, Burke JF, Wikler MA, Marino SK, et al.

J Infect Dis. 1992 Sep;166(3):556-60.

PMID:
1500739
14.

Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery.

Platt R, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, Bryan CS, Burke JF, Wikler MA, Marino SK, Holbrook KF, et al.

N Engl J Med. 1990 Jan 18;322(3):153-60.

15.
16.

Comparison of ceftizoxime versus combination therapy in the treatment of pelvic inflammatory disease (PID).

Wikler MA, Moonsammy GI, Hemsell DL.

J Chemother. 1989 Jul;1(4 Suppl):882-3. No abstract available.

PMID:
16312685
17.

Lack of correlation between in vitro susceptibility data of anaerobes to ceftizoxime and clinical response.

Wikler MA, Moonsammy GI, Nichols RL.

J Chemother. 1989 Jul;1(4 Suppl):660-1. No abstract available.

PMID:
16312580
18.

Coagulopathy associated with extended-spectrum cephalosporins in patients with serious infections.

Nichols RL, Wikler MA, McDevitt JT, Lentnek AL, Hosutt JA.

Antimicrob Agents Chemother. 1987 Feb;31(2):281-5.

19.

Clinical efficacy of cefonicid in the treatment of staphylococcal infections.

Lentnek AL, Evrard HM, Wikler MA, Sohn CA, Phillips SW.

Clin Ther. 1985;7(6):725-32.

PMID:
4075363

Supplemental Content

Loading ...
Support Center